Raxibacumab

(Raxibacumab®)

Raxibacumab

Drug updated on 11/9/2023

Dosage FormInjection (intravenous; 1700 mg/34 mL (50 mg/mL)
Drug ClassMonoclonal antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients with inhalational anthrax due to bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Product Monograph / Prescribing Information

Document TitleYearSource
Raxibacumab Prescribing Information.2021Emergent BioSolutions Inc., Gaithersburg, MD

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines